Education
About Us
Working with TipRanks
Follow Us
Novavax (NVAX)
NASDAQ:NVAX
NVAX Stock Chart & Stats
$8.70
-$1.22(-11.32%)
At close: 4:00 PM EST
$8.70
-$1.22(-11.32%)
Day’s Range― - ―
52-Week Range$5.01 - $10.64
Previous CloseN/A
Volume4.15M
Average Volume (3M)5.22M
Market Cap
$1.34B
Enterprise Value$1.39B
Total Cash (Recent Filing)$762.89M
Total Debt (Recent Filing)$251.14M
Price to Earnings (P/E)4.9
Beta1.91
Next Earnings
Mar 04, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.25
Shares Outstanding162,499,000
10 Day Avg. Volume4,364,744
30 Day Avg. Volume5,216,748
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)-1.96
Price to Sales (P/S)1.79
P/FCF Ratio-12.20
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue1.31
Enterprise Value/Gross Profit1.42
Enterprise Value/Ebitda3.39
Forecast
1Y Price Target
$11.17Price Target Upside28.39% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Licensing ValidationPfizer's non-exclusive license to use Matrix-M signals third-party validation of the adjuvant's commercial appeal and could encourage additional pharma partners to pursue similar collaborations.
Milestone RevenueA $125 million milestone tied to initiation of the Phase 3 CIC study would provide significant non-dilutive revenue while Novavax supplies Matrix-M and the partner handles development and commercialization.
Pipeline CompetitivenessMatrix-M's ability to enhance safety and effectiveness in RSV and shingles candidates could strengthen Novavax's internal pipeline and improve competitive positioning in those crowded vaccine markets.
Bears Say
Commercial Demand PressureSoft prescription script trends and uncertain COVID vaccine demand could make gaining share against established competitors difficult, pressuring sales and partner uptake of new Matrix-M-containing vaccines.
Limited Near-term ProgramsFew Matrix-M collaboration programs approaching clinical trials beyond one known candidate restrict near-term visibility for milestone receipts and royalty streams.
Milestone Timing RiskMaterial upside depends on successful late-stage trials and commercialization, and unclear timing of those development milestones could postpone revenue realization and valuation drivers.
Novavax News
NVAX FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was $5.01 and its highest was $10.64 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is $1.34B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Mar 04, 2026 which is in 21 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Nov 06, 2025. The company reported -$1.25 earnings per share for the quarter, missing the consensus estimate of -$1.196 by -$0.054.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.49.
How many shares outstanding does Novavax have?
Novavax has 162,499,000 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -$1.25 in its last earnings report, missing expectations of -$1.196. Following the earnings report the stock price went down -1.3%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in NVAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$11.17 (28.39% Upside)
$11.17 (28.39% Upside)
Blogger Sentiment
Bullish
NVAX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 979.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.10%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
NVAX Company Deck
NVAX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in strategic partnerships, cost reduction efforts, and financial improvements. However, there were notable challenges, including decreased product sales and a considerable net loss. The positive aspects slightly outweigh the negative, indicating a cautiously optimistic outlook.View all NVAX earnings summariesNVAX Stock 12 Month Forecast
Average Price Target
$11.17
▲(28.39% Upside)
Technical Analysis
Vir Biotechnology
―
Oric Pharmaceuticals
―
―
AbCellera Biologics
―
Sana Biotechnology
―
Ownership Overview
0.38% Insiders
12.37% Mutual Funds
0.01% Other Institutional Investors
68.30% Public Companies and Individual Investors